Tonight, CNBC released a bombshell article detailing multiple allegations of sexual abuse perpetrated by Trevor Milton, $NKLA founder, current largest shareholder (with ~24% ownership), recent Executive Chairman and former CEO.
In light of the latest, let’s discuss the company’s backers, partners and bankers that have all recently tried to absolve themselves of liability by assuring the market and the public of their extensive due-diligence on $NKLA.
Following our report, which contained details of dozens of material false statements by $NKLA, the company failed to even attempt to answer 43 of 53 questions we raised.
Instead, it addressed roughly 10 questions, largely confirming our findings, and ignored the rest.
Steve Girsky sponsored $NKLA's go-public transaction, brokered the $GM deal and is now Chairman.
Girsky claimed he brought “an army” to diligence Nikola prior to his involvement.
Given everything, one might have expected Girsky to resign. Instead, he’s now IN CHARGE.
Jeff Ubben formerly served as director and key shareholder of Valeant Pharmaceuticals prior to its spectacular collapse. His fund hand-picked Valeant’s CEO, who later settled SEC securities fraud charges...
Ubben now serves as director and Chair of $NKLA's corporate governance committee.
Per a recent interview with Bloomberg, Ubben can’t seem to understand why everyone is skeptical, insisting that Nikola’s partners must have done some due diligence.
Almost 39% of investment bank Cowen’s Q2 operating income was from its investment in $NKLA, according to its quarterly report.
Despite the massive conflict of interest, Cowen has maintained a street high price target of $79/share, insisting it has done its research on management
So which is it—did $NKLA's backers and partners not do any meaningful due diligence?
Or did they all do extensive vetting as they claimed, find the obvious false statements, faked product demos and sexual abuse allegations, then decide to support the company anyways?
$NKLA's brand has gone from tarnished to toxic.
Mary Barra should answer: Will GM put its 112-year brand at risk for $NKLA stock that will likely be worthless by the time $GM can sell, and for cash that likely won’t be there when it comes time to spend?
Additionally, for Bosch, CNH, and $NKLA's other remaining partners, how long are they going to continue to defend the indefensible in order to salvage locked-up shares and reputations? Are they better off on their own?
As to the inevitable retort of “Milton is out therefore this is all in the past”; does anyone actually believe that?
Milton still owns almost a quarter of the company, and $NKLA will be dealing with the aftermath of his “legacy” for years to come.
Per SEC filings:
Furthermore, in Milton’s place now stand a group of executives and directors who either missed everything or willfully ignored all these glaring issues on the promised path to riches.
On a positive note, we want to commend the women who have spoken out. It takes serious courage to share these extremely vulnerable experiences publicly, especially about a powerful billionaire who wishes to suppress them. Bravo
• • •
Missing some Tweet in this thread? You can try to
force a refresh
$EQIX is an $80 billion market cap data center REIT with over 260 facilities globally.
It has 10,000+ customers, ranging from small businesses to large cloud “hyperscaler” providers like Amazon, Microsoft and Google.
(2/x)
Even if you ignore our findings & take the financials of $EQIX at face value, the company trades at elevated levels; an ~86% premium to its peers on a price to forward AFFO basis and a ~59% premium on a price to forward FFO basis.
Our 4-month investigation into Temenos, involving interviews with 25 former employees, including senior leaders at the company, uncovered hallmarks of manipulated earnings and major accounting irregularities.
(2/n)
This includes evidence of roundtripped revenue, sham partnerships, rampant pulling forward of contract renewals, backdated contracts, excessive capitalization of seemingly non-existent R&D investments, and other classic accounting red flags.
$RENB is a biotech company with several preclinical drug candidates that is “committed to curing people with cancers and infectious diseases”.
Weeks ago, it voted to merge with “AI Health” company GEDi Cube, giving the company a pro-forma diluted market cap of ~$567m.
(2/n)
CEO Dr. Mark Dybul has a prestigious background:
(i) serving under Anthony Fauci at the National Institute of Health (NIH)
(ii) as Executive Director of the Global Fund to Fight AIDS, Tuberculosis, and Malaria and
(iii) as a tenured professor at Georgetown University
LifeStance is a $2.3 billion market cap mental health provider with 6,400 clinicians located across 33 U.S. states.
The company has grown its clinician base at 18% per year in a behavioral health market forecasted to grow ~5% per year until 2030. (2/n)
$LFST trades at a ~23% premium to its peers in the behavioral health industry, despite reporting in its most recent Q3 ’23 report: $188 million in losses over the last twelve months, $482 million in debt and lease obligations and a $716 million accumulated deficit.
In its complaint, the SEC alleges Mmobuosi and other defendants “booked billions of dollars’ worth of fictitious transactions through two Nigerian subsidiary companies Mmobuosi founded and controls”.
The complaint called Tingo Mobile a “sham” and “a fiction”, alleging that claimed assets, revenues, expenses, customers, and suppliers of Tingo Mobile were “virtually entirely fabricated” – and that the public co’s that control it have been “perpetrating an ongoing fraud”.